Intestinal Behçet’s disease complicated by myelodysplastic syndrome and secondary pulmonary alveolar proteinosis: a case report

Hiroshi Shimizu1,2, Shuzo Sato3*, Tomohiro Suzuki1†, Tomomi Sasajima4, Yosuke Takahata1, Nobuhiko Shinohara1, Kosuke Hideshima1, Yuko Yokokawa1, Nobuo Matsuhashi1, Osamu Ichii1, Mayumi Tai1, Yutaka Ejiri1, Kiori Yano4, Takayuki Ikezoe5, Hiromasa Ohira2 and Kiyoshi Migita3

Abstract

Background: Gastrointestinal lesions, which sometimes develop in Behçet’s disease (BD), are referred to as intestinal BD. Although rare, intestinal BD can be accompanied by myelodysplastic syndrome (MDS) with abnormal karyotype trisomy 8, which is refractory to immunosuppressive therapy. Pulmonary alveolar proteinosis is a rare lung complication of BD and MDS. Herein, we present an extremely rare case of intestinal BD presenting with MDS and several chromosomal abnormalities, followed by secondary pulmonary proteinosis.

Case presentation: A 58-year-old Japanese woman with a 3-year history of genital ulcers and oral aphthae was admitted to our hospital. The patient developed abdominal pain and persistent diarrhea. Colonoscopy revealed multiple, round, punched-out ulcers from the terminal ileum to the descending colon. Intestinal BD was diagnosed and the patient was treated with colchicine, prednisolone, and adalimumab. However, her symptoms were unstable. Bone marrow examination to investigate the persistent macrocytic anemia revealed the presence of trisomy 8, trisomy 9, and X chromosome abnormalities (48, +8, +9, X, i(X) (q10) in 12 out of the examined 20 cells). Based on her hypoplastic bone marrow, the patient was diagnosed with low-risk MDS (refractory anemia). At the age of 61, the patient developed pneumonia with fever and diffuse ground-glass opacities on the lung computed tomography (CT). Chest high-resolution CT and histopathology via transbronchial lung biopsy revealed the presence of pulmonary alveolar proteinosis (PAP). These findings combined with the underlying disease led to the diagnosis of secondary PAP.

Conclusions: Secondary pulmonary proteinosis may accompany intestinal BD with MDS and several chromosomal abnormalities. Physicians should pay attention to lung complications, such as PAP, in patients with intestinal BD complicated by MDS. Genetic abnormalities may be associated with the development of such diseases.

Keywords: Behçet’s disease, Myelodysplastic syndrome, Pulmonary alveolar proteinosis, Trisomy 8, X chromosome anomaly

Background

Behçet’s disease (BD) is a systemic inflammatory disorder of unknown etiology and is characterized by oral ulcers, genital ulcers, uveitis, skin lesions, and arthritis. Lesions in the gastrointestinal tract, central nervous system, and blood vessels sometimes accompany BD [1]. Gastrointestinal involvement in BD, called intestinal BD, results
in higher morbidity and mortality [2]. Myelodysplastic syndrome (MDS) with trisomy 8, a hematological disorder, may also be associated with intestinal BD [3–6]. Intestinal BD associated with trisomy-8-positive MDS is refractory to various immunosuppressive treatments, including tumor necrosis factor (TNF) inhibitors, and some patients require hematopoietic stem cell transplantation to achieve complete remission [5–7].

Pulmonary alveolar proteinosis (PAP) is a rare disorder with unknown etiology and is characterized by the accumulation of phospholipids and surfactant proteins in the alveolar lumen and terminal bronchiole [8–10]. PAP is classified into autoimmune, secondary, and congenital PAP [11]. In autoimmune PAP, the granulocyte/macrophage colony-stimulating factor (GM-CSF) cascade is disrupted by high levels of GM-CSF antibody in the lungs [12]. Secondary PAP (SPAP) accompanies underlying diseases; surfactant clearance is impaired by abnormal numbers and functions of alveolar macrophages in secondary PAP [9, 11, 13]. MDS is a major underlying condition that leads to SPAP [8, 11]. Lung complications in BD patients are uncommon and intestinal BD with MDS complicated by PAP is particularly rare [8]. Here, we present an extremely rare case of intestinal BD with MDS.

Case presentation

A 58-year-old Japanese woman with a 3-year history of genital ulcers and oral aphthae was admitted to our hospital. She had a history of uterine fibroids and thrombocytopenia during pregnancy. Her family history included hypertension and diabetes in her mother and MDS in her offspring. A year ago on admission, she developed abdominal pain and persistent diarrhea. Colonoscopy revealed multiple colonic ulcers, and she was referred to our hospital. On physical examination, we found erythema nodosum without uveitis on the left forearm. Laboratory tests revealed macrocytic anemia (red blood cell count, 251 × 10⁴/μl; hemoglobin level, 9.3 g/dl). White blood cell and platelet counts were 4800/μl and 14.3 × 10⁴/μl, respectively. Serum C reactive protein levels were 0.35 mg/dl and anti-nuclear antibody was negative. Human leukocyte antigen analysis was positive for B51 and A26. Colonoscopy showed multiple, round, punched-out ulcers from the terminal ileum to the descending colon (Fig. 1a, b). Intestinal Behçet’s disease (BD) was diagnosed, and she received 3600 mg of mesalazine, 0.5 mg of colchicine, and 30 mg of oral prednisolone per day. Adalimumab, a TNF inhibitor was also added for maintenance therapy. However, during steroid tapering, her abdominal symptoms relapsed. Persistent anemia was observed and bone marrow examination was performed. The results revealed the presence of trisomy 8, trisomy 9, and X chromosome abnormalities (48, +8, +9, X, i(X) (q10) in 12 out of the 20 cells examined; Fig. 2). The patient’s bone marrow was hypoplastic with the appearance of micromegakaryocytes and <1% of atypical cells, resulting in the diagnosis of low-risk MDS (refractory anemia). At the age of 60, Infliximab (5 mg/kg) against refractory intestinal BD was initiated instead of Adalimumab. Infliximab was temporary effective for abdominal symptoms, however, she developed pneumonia with
fever at the age of 61. Chest X-ray and lung computed tomography (CT) showed diffuse ground-glass opacities in both lungs (Fig. 3a, b). High-resolution chest CT and histopathology via transbronchial lung biopsy revealed the presence of pulmonary alveolar proteinosis (Fig. 4). Her serum GM-CSF concentration was 4.3 pg/ml (normal range, < 5 pg/ml) and an anti-GM-CSF antibody was negative. Based on findings with the underlying disease, a
diagnosis of SPAP was established. She was treated with infliximab (5 mg/kg) for active intestinal BD for every 4 weeks and received whole lung lavage to improve respiratory symptoms with SPAP. She is now preparing to receive bone marrow transplantation as a curative treatment.

**Discussion and conclusions**

We present a case of intestinal BD accompanying by MDS with several chromosomal abnormalities, including trisomy 8. The patient’s symptoms were refractory to immunosuppressive therapy and complicated by PAP without anti-GM-CSF antibodies, indicating SPAP. To the best of our knowledge, this is the first case of intestinal BD associated with trisomy-8-positive MDS accompanied by SPAP and several chromosomal abnormalities, including chromosome X. Cases of intestinal BD with trisomy-8-positive MDS complicated by SPAP are extremely rare; only two such cases have been described in the literature (Table 1) [8]. Including our case, two of the three cases were female. Past cases showed refractory anemia in MDS type and no eye lesions of BD symptoms were found. Our patient only had HLA-B51, trisomy 9, and X chromosome anomaly. Chest CT showed diffuse ground-glass opacities in both lungs in all patients.

Despite treatment with steroids and immunosuppressants, including TNF inhibitors, the prognosis of such cases remained poor because of severe infection and in part, deterioration of PAP [8]. Indeed, the treatment of SPAP in patients with MDS is challenging [11, 14]. Whole lung lavage can be considered, but the effect of this treatment is temporary [10]. Zhang et al. have reported that patients with SPAP secondary to hematological diseases had poor survival compared with those with other causes, partly due to infections [15]. Conversely, a previous report has described successful treatment by bone marrow transplantation for patients with SPAP and MDS [16]. Bone marrow transplantation can be considered in these cases but is not applicable for all patients. In Japan, Ishii et al. reported that patients with MDS and SPAP were treated with bone marrow transplantation; however, three of seven patients died from pneumonia within 3 months of transplantation [11]. In another report, patients with intestinal BD and trisomy-8-positive MDS who were refractory to immunosuppressive therapy received bone marrow transplantation as a cure for both diseases [6, 7]. Transplantation was

---

**Table 1** Summary of intestinal Behçet’s disease patients with myelodysplastic syndrome associated with secondary pulmonary alveolar proteinosis

| Author/year (reference) | Age/sex | MDS type | BD symptoms | Chromosomal abnormalities/HLA | Respiratory symptoms | HRCT findings (GGO pattern) | Treatment before MDS onset (duration, years) | Outcome |
|-------------------------|---------|----------|-------------|-----------------------------|-------------------|---------------------------|---------------------------------|---------|
| Handa/2014 [8]          | 49/F    | RA       | G, I, O, S | Trisomy 8/HLA-B51-          | None              | Diffuse                   | Cyclosporine A, Prednisolone, Sulfasalazine, TNF-inhibitor (14 years) | Dead    |
| Handa/2014 [8]          | 33/M    | RA       | I, O, S    | Trisomy 8/HLA-B51-          | Cough             | Diffuse                   | Azathioprine, Prednisolone, Sulfasalazine, TNF inhibitor (5 years) | Dead    |
| Present case/2021       | 58/F    | RA       | G, I, O, S | Trisomy 8, Trisomy 9, i(X)(q10)/HLA-B51+ | Cough, Fever     | Diffuse                   | Colchicine, Methotrexate, Prednisolone, TNF inhibitor (3 years) | Alive   |

BD, Behçet’s disease; G, genital ulcer; GGO, ground-glass opacity; HLA, human leukocyte antigen; HRCT, high-resolution computed tomography; I, intestinal lesions; MDS, myelodysplastic syndrome; O, oral ulcer; RA, Refractory anemia; S, skin lesion; TNF, tumor necrosis factor
successful in some patients, but severe infections were a major issue preventing recovery [6]. Further accumulation of such cases is needed to establish an appropriate treatment. The distinct mechanism underlying the development of intestinal BD associated with MDS and SPAP is unclear; however, several genetic abnormalities may be involved in the pathogenesis.

Trisomy 8 was postulated to be involved in the inflammatory processes of intestinal BD through the production of abnormal inflammatory cytokines, such as GM-CSF, interleukin (IL)-1beta, IL-6, IL-8, IL-17, IL-18, TNF-alpha, and interferon-gamma [17, 18]. The upregulation of inflammatory genes was detected in CD34-positive progenitor cells in patients with MDS and trisomy 8 [19]. Inflammation may influence the production of abnormal macrophages in the lungs, resulting in PAP. Furthermore, Moriyama et al. have reported that alveolar cells obtained from bronchoalveolar lavage had trisomy 8, indicating alveolar macrophages were likely differentiated from abnormal hematopoietic stem cells with trisomy 8 [9]. This hypothesis is supported by the fact that hematopoietic stem cell transplantation has alleviated MDS with SPAP patients [16]. In contrast, trisomy 9 is rarely reported and is chiefly associated with myeloproliferative and myelodysplastic disorders, such as MDS [20]. Disrupted GM-CSF signaling is a major cause of PAP. GM-CSF regulates alveolar surfactant homeostasis. Moreover, genetic abnormalities of the GM-CSF receptor α-chain, encoded by the X-chromosome, can cause PAP [21]. The X chromosome abnormalities might have contributed to the development of PAP by affecting GM-CSF signaling even in the absence of anti-GM-CSF autoantibodies in this case. Taken together, these genetic abnormalities can synergistically affect each other, altering organ environments including inflammatory cytokine expressions such as GM-CSF, abnormal cell proliferation and finally resulted in the manifestation of SPAP in intestinal BD with MDS [9, 16–18].

In conclusion, intestinal BD with MDS may be accompanied by lung complications in rare instances. Thus, attention should be paid to the development of PAP as a lung complication in patients with intestinal BD with trisomy-8 positive MDS. Genetic and hematological investigations are important in establishing an early diagnosis in such cases. Several chromosomal abnormalities, including trisomy 8 and X chromosome anomaly, may contribute to the development of PAP in combination with BD symptoms, which impacts patient outcomes.

Abbreviations
BD: Behçet’s disease; CD: Cluster of differentiation; CT: Computed tomography; GM-CSF: Granulocyte/macrophage colony-stimulation factor; GM-CSFR: Granulocyte/macrophage colony-stimulation factor receptor; HSCT: Hematopoietic stem cell transplantation; IL: Interleukin; MDS: Myelodysplastic syndrome; PAP: Pulmonary alveolar proteinosis; SPAP: Secondary pulmonary alveolar proteinosis; TNF: Tumor necrosis factor.

Acknowledgements
The authors are grateful to Enago (http://www.enago.jp) for the English language review.

Author contributions
H.S., TSU, SS, and K.M. made the concept and design of the report and interpreted the clinical data. H.S., SS, and K.M. critically revised the manuscript. H.S., TSU, TSA, YT, NS, K.H, YY, NM, OI, MT, YE, KY, TJ, HO, and K.M. were involved in clinical care of this patient and reviewed similar reported cases of the literature. All authors approved the final version of the manuscript to be published and agree to be accountable for all aspects of the work.

Funding
Not applicable.

Availability of data and materials
Data sharing is not applicable to this article because no datasets were generated or analyzed during the current study.

Declarations
Ethics approval and consent to participate
Authors’ institution does not require ethical approval for publication of a single case report. Written informed consent was obtained from the patient.

Consent for publication
Written informed consent about the publication was obtained from the patient. A copy of the signed, written informed consent for publication form is available for review by the Editor of this journal.

Competing interests
The authors declare there are no competing interests in this study.

Author details
1 Department of Gastroenterology, Fukushima Rosai Hospital, Uchigo, Iwaki, Fukushima 973-8403, Japan. 2 Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan. 3 Department of Rheumatology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan. 4 Department of Rheumatology, Fukushima Rosai Hospital, Iwaki, Japan. 5 Department of Hematology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Received: 28 April 2021   Accepted: 8 December 2021
Published online: 20 December 2021

References
1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341(17):1284–91.
2. Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behçet's disease: a review. World J Gastroenterol. 2015;21(13):3801–12.
3. Adachi Y, Tsutsumi A, Murata H, Takemura H, Chino Y, Takahashi R, et al. Behçet's disease accompanied by myelodysplastic syndrome with trisomy 8: two case reports and a review of 15 Japanese cases. Mod Rheumatol. 2003;13(1):90–4.
4. Ahn JK, Cha HS, Kho EM, Kim SH, Kim YG, Lee CK, et al. Behçet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatol. 2008;47(8):1228–30.
5. Toyonaga T, Nakase H, Matsuura M, Minami N, Yamada S, Honzawa Y, et al. Refractoriness of intestinal Behçet's disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature. Digestion. 2013;88(4):217–21.
6. Asano T, Sato S, Furuya M, Takahashi H, Shishichima-Nakamura A, Ohkawa H, et al. Intestinal Behçet disease associated with myelodysplastic syndrome.
syndrome accompanying trisomy 8 successfully treated with abdominal surgery followed by hematopoietic stem cell transplantation: a case report. Medicine (Baltimore). 2019;98:e17979.
7. Soysal T, Salihoğlu A, Esatoğlu SN, Gültürk E, Eşkazan AE, Hatemi G, et al. Bone marrow transplantation for Behçet’s disease: a case report and systematic review of the literature. Rheumatology (Oxford). 2014;53(6):1136–41.
8. Handa T, Nakatsue T, Baba M, Takada T, Nakata K, Ishii H. Clinical features of three cases with pulmonary alveolar proteinosis secondary to myelodysplastic syndrome developed during the course of Behçet’s disease. Respir Investig. 2014;52:75–9.
9. Moriyama M, Yano T, Furukawa T, Takada T, Ushiki T, Masuko M, et al. Possible involvement of lung cells harboring an abnormal karyotype in the pathogenesis of pulmonary alveolar proteinosis associated with myelodysplastic syndrome. Ann Am Thorac Soc. 2015;12(8):1251–3.
10. Suzuki T, Trapnell BC. Pulmonary alveolar proteinosis syndrome. Clin Chest Med. 2016;37(3):431–40.
11. Ishii H, Seymour JF, Tazawa R, Inoue Y, Uchida N, Nishida A, et al. Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulm Med. 2014;14:37.
12. Kitamura T, Tanaka N, Watanabe J, Uchida, Kanegasaki S, Yamada Y, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999;190(6):875–80.
13. Nishida A, Miyamoto A, Yamamaoto H, Nishida A, Uchida N, Izutsu K, et al. Possible association of trisomy 8 with secondary pulmonary alveolar proteinosis in myelodysplastic syndrome. AM J Respir Crit Care Med. 2011;184(2):279–80.
14. Hashimoto M, Itonaga H, Nannya Y, Taniguchi H, Fukuda Y, Furumoto T, et al. Secondary pulmonary alveolar proteinosis following treatment with azacitidine for myelodysplastic syndrome. Intern Med. 2020;59(8):1081–6.
15. Zhang D, Tian X, Feng R, Guo X, Wang P, Situ Y, et al. Secondary pulmonary alveolar proteinosis: a single-center retrospective study (a case series and literature review). BMC Pulm Med. 2018;18(1):15. https://doi.org/10.1186/s12890-018-0590-z.
16. Tabata S, Shimizu S, Murase K, Takuchi Y, Inoue D, Kimura T, et al. Successful allogeneic bone marrow transplantation for myelodysplastic syndrome complicated by severe pulmonary alveolar proteinosis. Int J Hematol. 2009;90(3):407–12.
17. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients: Relationship with disease activity. Scand J Rheumatol. 2002;31(4):205–10.
18. Hasogawa H, Iwamasa K, Hatta N, Fujita S. Behçet’s disease associated with myelodysplastic syndrome with elevated levels of inflammatory cytokines. Mod Rheumatol. 2003;13(4):350–5.
19. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 2004;104(13):4210–8.
20. Cournoyer D, Noel P, Schmidt MA, Dewald GW. Trisomy 9 in hematologic disorders: possible association with primary thrombocytosis. Cancer Genet Cytoenet. 1987;27(1):73–8.
21. Martinez-Moczygemba M, Doan ML, Eledemir O, Fan LL, Cheung SW, Lei JT, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFAlpha gene in the X chromosome pseudoautosomal region 1. J Exp Med. 2008;205(12):2711–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.